The unusual blood cots experienced by four Johnson & Johnson (J&J) vaccine recipients have attracted the E.U.’s attention, which launched a probe on Friday, April 9, to study the possible link between the vaccine and the conditions.

According to the European Medicines Agency, four severe cases of unusual clots with low platelets have been identified since receiving the Chinese Communist Party (CCP) Virus or COVID-19 vaccine, one of which was fatal (EMA).

Johnson & Johnson’s coronavirus vaccine was advertised as 67% effective in infection prevention and 100% capable of preventing hospital admissions and death from the virus. Its commonly called the Janssen vaccine and is known widely for being a one-shot vaccine.

The J & J vaccine requires only one shot to be effective, whereas others require a follow-up dose making it more desirable for many.

Currently, the shot is only authorized in the United States. The European Union approved the vaccine last month, and distribution is due for launch in the region in a couple of weeks. J&J and AstraZeneca are among the four vaccines authorized by the E.U. 

In addition, scrutiny by the European Medicines Agency’s safety committee also includes the AstraZeneca CCP Virus or COVID-19 vaccine, which is also suspected of causing irregular blood clots. The agency is looking at records of capillary leak syndrome in five people who have received the vaccine and experienced blood vessel swelling and a drop in blood pressure.

“It’s too early to comment on the signal of capillary leak with the AZ vaccine, or clots with the Janssen vaccine, but from what we’ve seen in the last few weeks, the EMA’s PRAC (Pharmacovigilance Risk Assessment Committee) will doubtless assess all the evidence they have as thoroughly and quickly as possible,” said Ian Douglas, professor of pharmacoepidemiology at London School of Hygiene & Tropical Medicine.

In an emailed statement, J&J, while acknowledging the reports on the blood clot cases, declared that “no clear causal relationship has been established between these rare events and the Janssen COVID-19 vaccine.” Reuters reports that the company is collaborating with regulators on providing its database for assessment. 

Nearly 5 million people in the United States had received J&J’s vaccine as of Thursday morning, according to the U.S. Centers for Disease Control and Prevention.

However, drug watchdogs have stressed that the benefits of the vaccine outweigh the risks.

Public Health England (PHE) said coronavirus (CCP Virus) vaccines had prevented 10,400 deaths in people aged 60 and over. As of yesterday, 31.81 million first jabs had been given.

This week’s update from regulators which noted a correlation between the vaccine and rare blood clots has prompted the UK, together with several European and Asian countries, to issue limitations on the use of AstraZeneca’s vaccine in young people, SkyNews discloses. 

Dr. Sam Fazeli, an analyst with Bloomberg Intelligence, says that adenovirus technologies applied in the AstraZeneca vaccine have been associated with clotting in other settings, reported straitstimes.

At present, similar effects have not occurred with Pfizer and Moderna shots.